Our vaccine technologies and CDMO services have a global impact, used in collaborations, contracts, and partnerships worldwide. Explore some of the projects that are testament of our commitment to vaccine innovation and development.
Coxsackie virus B (CVB) has been found in the pancreas of ~60% of patients with type 1 diabetes. In fact, persistent CVB infection is significantly associated with the development of the disease and of celiac disease.
The pentavalent inactivated CVB vaccine, PRV-101, is a potential vaccine for acute CVB infection and thus, may potentially prevent of up to 50% of type 1 diabetes and possibly 20% of celiac disease cases. We developed and manufactured for the US company ProventionBio the clinical trial material of PRV-101. In March 2022, ProventionBio has reported positive results from the final analysis of its first-in-human PROVENT study of PRV-101. In 2023, ProventionBio was acquired by Sanofi.
The Dutch company Cimcure has identified protein targets in tumor vasculature that can be leveraged to destroy endothelial cells, cutting off blood supply to cancer cells and thus, preventing tumor growth. The company conceptualized a vaccine consisting of the target protein vimentin conjugated to a proprietary engineered bacterial sequence. When administered, the vaccine induces high levels of antibodies against the target protein, which triggers an immune response against tumor blood vessels. The vaccine has shown preclinical proof of concept in colon cancer, melanoma, and glioblastoma. Intravacc provides CDMO services to Cimcure involving its E.co-Vacc technology to further develop the vaccine.
The ingestion of Shigella flexneri 2a causes shigellosis, a disease associated with diarrhea and other gastrointestinal symptoms. Roughly 250 million cases of shigellosis occur annually in low- and middle-income countries.
Intravacc collaborated with the Institut Pasteur Paris in an EU funded project (Stopenterics, European Community's Seventh Framework Programme, FP7/2007-2013) to develop a GMP-grade scalable production process to manufacture vaccine material for a phase I clinical trial to test a conjugate vaccine candidate. The phase I clinical trial was successful and two ongoing Phase II studies, consisting of an age-deescalating study in Kenya and a Controlled Human Infection Model in the USA, are ongoing.
Amyotrophic lateral sclerosis (ALS) is a rare, progressive, and fatal neurodegenerative disease that results in the loss of motor neurons in the brain and spinal cord. Currently, patients die 3-5 years after diagnosis, and treatments are limited. Roughly 5-10% of ALS patients of European descent carry a mutation called C9orf72 that causes the aggregation of neurotoxic repeat proteins. Intravacc is working with the German Center of Neurodegenerative Diseases (DZNE) in an EU-funded project called GA-VAX to develop a preventive and therapeutic vaccine for this subtype of ALS. The vaccine candidate stimulates an immune response against the neurotoxic proteins and has shown benefits in preventing and treating neurodegeneration in a mouse model. The candidate is being developed for a First-in-Human phase I/II clinical study.
You can send us an email:
info@intravacc.nl
Reach out to Business Development:
BD@intravacc.nl
Or pick up the phone:
+31 30 792 03 00
You can also just fill out the contact form on the right.
We look forward to hearing from you!
